Director

Department / Division:
Radiology / Nuclear Medicine

Address:
DUMC 3949
Durham, NC 27710

Appointment Telephone:
919-684-7245

Office Telephone:
919-684-7244

Fax Telephone:
919-684-7135

• MD, Washington University in St. Louis School of Medicine (Missouri), 1968

• Medicine, Royal Victoria Hospital (Canada), 1970
• Nuclear Medicine, Mallinckrodt Institute of Radiology (Missouri), 1972-1974

Clinical Interests:
General nuclear medicine, positron emission tomography, radionuclide therapy

Research Interests:
Tumor characterization by radionuclide imaging techniques is the general theme of the research.  The methods of imaging include the use of planar gamma cameras, single photon emission computed tomography (SPECT) and positron emission tomography (PET).  The radiopharmaceuticals that are used include FDA-approved agents, IND agents (monoclonal antibodies for diagnosis and therapy, I-131 MIBG for therapy of neuroendocrine tumors), Radioactive Drug Research Committee approved agents (0-15 water for tumor blood flow, F-18 labeled agents for PET imaging of tumors etc.), and F-18 fluorodexoyglucose for the study of metabolism.  The research projects include the quantification of pulmonary perfusion by SPECT imaging of patients with pulmonary cancer before and after radiation therapy, determination of kinetics and radiation dosimetry of radionuclide labeled monoclonal antibodies administered for therapeutic purposes, radionuclide therapy of neuroendocrine tumors, the metabolic characterization of brain tumors before and after therapy, and development of new methods for characterizing neuroendocrine tumors.  The effects of chemotherapy, radiation therapy, and surgery on tumor and normal tissue metabolism are being studied using PET.  Methods for improving the quantitative integrity of the information provided from the radiopharmaceuticals that are administered are being developed in the SPECT and PET laboratories.  This research bridges the basic science developments and the clinical expertise in imaging.